1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Indication 1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication: 2017 VS 2021 VS 2028 1.2.2 Augmentation Therapy 1.2.3 Cystic Fibrosis(CF) 1.2.4 Non-CF Bronchiectasis(NCFB) 1.2.5 Diabetes 1.2.6 Other 1.3 Market by End Users 1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users: 2017 VS 2021 VS 2028 1.3.2 COPD 1.3.3 Cystic Fibrosis(CF) 1.3.4 Non-CF Bronchiectasis(NCFB) 1.3.5 Diabetes 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2017-2028) 2.2 Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region 2.2.1 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2017-2022) 2.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2023-2028) 2.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics 2.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends 2.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers 2.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges 2.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue 3.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2017-2022) 3.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2017-2022) 3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Alpha 1 Antitrypsin Deficiency Treatment Revenue 3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio 3.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2021 3.5 Alpha 1 Antitrypsin Deficiency Treatment Key Players Head office and Area Served 3.6 Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service 3.7 Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by Indication 4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2017-2022) 4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028) 5 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End Users 5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2017-2022) 5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2023-2028) 6 North America 6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028) 6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) 6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028) 7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) 7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028) 8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) 8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028) 9.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) 9.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2017-2028) 10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) 10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Pfizer 11.1.1 Pfizer Company Detail 11.1.2 Pfizer Business Overview 11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.1.5 Pfizer Recent Development 11.2 GlaxoSmithKline 11.2.1 GlaxoSmithKline Company Detail 11.2.2 GlaxoSmithKline Business Overview 11.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.2.5 GlaxoSmithKline Recent Development 11.3 AstraZeneca 11.3.1 AstraZeneca Company Detail 11.3.2 AstraZeneca Business Overview 11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.3.5 AstraZeneca Recent Development 11.4 Boehringer Ingelheim 11.4.1 Boehringer Ingelheim Company Detail 11.4.2 Boehringer Ingelheim Business Overview 11.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.4.5 Boehringer Ingelheim Recent Development 11.5 Teva Pharmaceutical Industries 11.5.1 Teva Pharmaceutical Industries Company Detail 11.5.2 Teva Pharmaceutical Industries Business Overview 11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.5.5 Teva Pharmaceutical Industries Recent Development 11.6 Takeda 11.6.1 Takeda Company Detail 11.6.2 Takeda Business Overview 11.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.6.5 Takeda Recent Development 11.7 Baxter 11.7.1 Baxter Company Detail 11.7.2 Baxter Business Overview 11.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.7.5 Baxter Recent Development 11.8 Grifols 11.8.1 Grifols Company Detail 11.8.2 Grifols Business Overview 11.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.8.5 Grifols Recent Development 11.9 CSL Behring 11.9.1 CSL Behring Company Detail 11.9.2 CSL Behring Business Overview 11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.9.5 CSL Behring Recent Development 11.10 Kamada Ltd 11.10.1 Kamada Ltd Company Detail 11.10.2 Kamada Ltd Business Overview 11.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.10.5 Kamada Ltd Recent Development 11.11 Chiesi Pharmaceuticals 11.11.1 Chiesi Pharmaceuticals Company Detail 11.11.2 Chiesi Pharmaceuticals Business Overview 11.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.11.5 Chiesi Pharmaceuticals Recent Development 11.12 Kedrion Group 11.12.1 Kedrion Group Company Detail 11.12.2 Kedrion Group Business Overview 11.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.12.5 Kedrion Group Recent Development 11.13 Vertex Pharmaceuticals 11.13.1 Vertex Pharmaceuticals Company Detail 11.13.2 Vertex Pharmaceuticals Business Overview 11.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.13.5 Vertex Pharmaceuticals Recent Development 11.14 ProMetic Life Sciences 11.14.1 ProMetic Life Sciences Company Detail 11.14.2 ProMetic Life Sciences Business Overview 11.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction 11.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) 11.14.5 ProMetic Life Sciences Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Augmentation Therapy Table 3. Key Players of Cystic Fibrosis(CF) Table 4. Key Players of Non-CF Bronchiectasis(NCFB) Table 5. Key Players of Diabetes Table 6. Key Players of Other Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth by End Users (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million) Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2017-2022) Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2023-2028) Table 13. Alpha 1 Antitrypsin Deficiency Treatment Market Trends Table 14. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers Table 15. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges Table 16. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2017-2022) & (US$ Million) Table 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players (2017-2022) Table 19. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2021) Table 20. Ranking of Global Top Alpha 1 Antitrypsin Deficiency Treatment Companies by Revenue (US$ Million) in 2021 Table 21. Global 5 Largest Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue (CR5 and HHI) & (2017-2022) Table 22. Key Players Headquarters and Area Served Table 23. Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service Table 24. Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2017-2022) & (US$ Million) Table 27. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2017-2022) Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028) & (US$ Million) Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2023-2028) Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2017-2022) & (US$ Million) Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2017-2022) Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2023-2028) & (US$ Million) Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2023-2028) Table 34. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million) Table 35. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million) Table 36. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million) Table 37. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million) Table 38. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million) Table 39. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2023-2028) & (US$ Million) Table 40. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million) Table 41. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million) Table 42. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2017-2022) & (US$ Million) Table 43. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2023-2028) & (US$ Million) Table 44. Pfizer Company Detail Table 45. Pfizer Business Overview Table 46. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Table 47. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 48. Pfizer Recent Development Table 49. GlaxoSmithKline Company Detail Table 50. GlaxoSmithKline Business Overview Table 51. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Table 52. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 53. GlaxoSmithKline Recent Development Table 54. AstraZeneca Company Detail Table 55. AstraZeneca Business Overview Table 56. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Table 57. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 58. AstraZeneca Recent Development Table 59. Boehringer Ingelheim Company Detail Table 60. Boehringer Ingelheim Business Overview Table 61. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Table 62. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 63. Boehringer Ingelheim Recent Development Table 64. Teva Pharmaceutical Industries Company Detail Table 65. Teva Pharmaceutical Industries Business Overview Table 66. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Table 67. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 68. Teva Pharmaceutical Industries Recent Development Table 69. Takeda Company Detail Table 70. Takeda Business Overview Table 71. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Table 72. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 73. Takeda Recent Development Table 74. Baxter Company Detail Table 75. Baxter Business Overview Table 76. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Table 77. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 78. Baxter Recent Development Table 79. Grifols Company Detail Table 80. Grifols Business Overview Table 81. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Table 82. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 83. Grifols Recent Development Table 84. CSL Behring Company Detail Table 85. CSL Behring Business Overview Table 86. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Table 87. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 88. CSL Behring Recent Development Table 89. Kamada Ltd Company Detail Table 90. Kamada Ltd Business Overview Table 91. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Table 92. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 93. Kamada Ltd Recent Development Table 94. Chiesi Pharmaceuticals Company Detail Table 95. Chiesi Pharmaceuticals Business Overview Table 96. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentProduct Table 97. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 98. Chiesi Pharmaceuticals Recent Development Table 99. Kedrion Group Company Detail Table 100. Kedrion Group Business Overview Table 101. Kedrion Group Alpha 1 Antitrypsin Deficiency TreatmentProduct Table 102. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 103. Kedrion Group Recent Development Table 104. Vertex Pharmaceuticals Company Detail Table 105. Vertex Pharmaceuticals Business Overview Table 106. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentProduct Table 107. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 108. Vertex Pharmaceuticals Recent Development Table 109. ProMetic Life Sciences Company Detail Table 110. ProMetic Life Sciences Business Overview Table 111. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency TreatmentProduct Table 112. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Table 113. ProMetic Life Sciences Recent Development Table 114. Research Programs/Design for This Report Table 115. Key Data Information from Secondary Sources Table 116. Key Data Information from Primary Sources List of Figures Figure 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication: 2021 VS 2028 Figure 2. Augmentation Therapy Features Figure 3. Cystic Fibrosis(CF) Features Figure 4. Non-CF Bronchiectasis(NCFB) Features Figure 5. Diabetes Features Figure 6. Other Features Figure 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users in 2021 & 2028 Figure 8. COPD Case Studies Figure 9. Cystic Fibrosis(CF) Case Studies Figure 10. Non-CF Bronchiectasis(NCFB) Case Studies Figure 11. Diabetes Case Studies Figure 12. Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2021 VS 2028 Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2021 Figure 17. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2021) Figure 18. The Top 10 and 5 Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2021 Figure 19. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 20. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2017-2028) Figure 21. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2017-2028) Figure 25. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. France Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2017-2028) Figure 33. China Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. India Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2017-2028) Figure 41. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2017-2028) Figure 45. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 46. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 47. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 48. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 49. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 50. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 51. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 52. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 53. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 54. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 55. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 56. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 57. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 58. Kedrion Group Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 59. Vertex Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 60. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) Figure 61. Bottom-up and Top-down Approaches for This Report Figure 62. Data Triangulation Figure 63. Key Executives Interviewed

Pfizer GlaxoSmithKline AstraZeneca Boehringer Ingelheim Teva Pharmaceutical Industries Takeda Baxter Grifols CSL Behring Kamada Ltd Chiesi Pharmaceuticals Kedrion Group Vertex Pharmaceuticals ProMetic Life Sciences